2017 Wilding JPH et al
It would only make sense that if glutathione helps heal the gut, it must also improve immunity since our immune system is located in our gut
The Lamont administration insists it is complying with state law, which does not mention covering GLP-1s specifically, only weight loss drugs in general
Alternative medication classes should be considered if GLP-1 therapy proves intolerable: SGLT2 inhibitors (such as dapagliflozin, empagliflozin) for type 2 diabetes, which work via a completely different mechanism and rarely cause gastrointestinal side effects DPP-4 inhibitors (such as sitagliptin, linagliptin), which enhance endogenous GLP-1 activity more gently Metformin remains first-line for type 2 diabetes, though it can also cause gastrointestinal side effects Orlistat for weight management, though this also has gastrointestinal side effects of a different nature For weight management specifically, NICE recommends a comprehensive approach including dietary modification, increased physical activity, and behavioural interventions, with or without pharmacotherapy

In the realm of diabetes care, semaglutide plays a crucial role in improving insulin sensitivity, reducing A1C levels (an important marker of long-term blood sugar control), and even decreasing the risk of cardiovascular complications
Off-Label Marketing Risk Manufacturers of GLP-1 medications may face regulatory scrutiny and legal risks if they promote their products for off-label use or disseminate inaccurate and misleading information